HS Optimus Holdings Limited Announces Strategic Acquisition of Medicorp Sdn Bhd
Key Highlights of the Transaction
- Acquisition Agreement: HS Optimus Holdings Limited (“HS Optimus”) has entered into a Sales and Purchase Agreement (SPA) to acquire 7,500 ordinary shares of Medicorp Sdn Bhd (“Medicorp”), representing 30% of Medicorp’s total issued share capital.
- Put Option: The Seller, Lee Rui Ren, is granted a put option to require HS Optimus (or its nominated subsidiary) to purchase up to 4,750 additional shares (19% of Medicorp), exercisable within three years.
- Medicorp Profile: Medicorp is a Brunei-based supplier of medical equipment and consumables, with an audited net tangible assets (NTA) of B\$3.22 million and net profits of B\$1.47 million for FY2025.
- Purchase Consideration: Total consideration is S\$4.2 million, split between up to S\$1 million in new HS Optimus shares and the balance in cash.
- Valuation: The exercise price for the put option is S\$560 per Medicorp share, with an aggregate value of S\$2.66 million for all option shares, based on a S\$14 million economic valuation of Medicorp.
- Dividend Guarantee: HS Optimus is guaranteed a minimum annual dividend of S\$300,000 for three years, with performance bonuses for yields above 9%.
- Financial Effects: The transaction is expected to increase the Group’s net profit and earnings per share (EPS), though NTA per share will decrease marginally due to the share issuance.
- Completion Date: Subject to conditions, completion is expected by 20 July 2026.
Details Investors Should Know
Transaction Structure and Payment
- HS Optimus will issue up to 185,185,185 new shares for both the initial acquisition and the put option at S\$0.0054 per share, a 10% discount to the recent market price.
- The total new shares represent 6.9% of the existing issued shares and 6.4% of the enlarged issued share capital post-acquisition.
- Cash consideration will be funded from internal resources.
Conditions Precedent
- The acquisition is subject to extensive conditions, including satisfactory due diligence, completion of an independent valuation, execution of a shareholders’ agreement, regulatory approvals, and no material adverse changes in Medicorp’s business.
- Medicorp may declare a pre-completion dividend (S\$2.5 million), which will be converted into an unsecured shareholder loan, with strict repayment conditions to safeguard working capital and distributable profits.
Price-Sensitive Points for Shareholders
- The SPA and put option terms could materially increase HS Optimus’s earnings. The guaranteed dividend and performance bonus could provide recurring income and earnings visibility for three years, enhancing shareholder value.
- The issuance of a large number of new shares at a discount could be dilutionary, impacting NTA per share and potentially affecting share price.
- The acquisition will not result in a change of control, but will strengthen HS Optimus’s presence in the medical supply industry with access to Medicorp’s established customer base including Brunei hospitals and oil & gas companies.
- Relative figures under SGX Catalist Rule 1006 show significant contribution to profit and market cap, making this a “disclosable transaction” likely to interest investors.
- Completion is not guaranteed until all conditions precedent are met; investors should monitor further announcements for material developments.
Financial Impact (Pro Forma)
| Before Transaction | After Acquisition | After Full Transaction | |
|---|---|---|---|
| Issued Capital (S\$) | 103,170,633 | 104,170,633 | 105,170,633 |
| No. of Shares | 5,380,556,316 | 5,565,741,501 | 5,750,926,686 |
| NTA (S\$’000) | 49,066 | 50,000 | 51,000 |
| NTA per Share (cents) | 0.91 | 0.90 | 0.89 |
| Net Profit (S\$’000) | 2,748 | 3,124 | 3,402 |
| EPS (cents) | 0.05 | 0.06 | 0.06 |
Shareholder and Regulatory Matters
- No new directors are proposed in connection with the transaction.
- The seller is related to substantial shareholders but not to directors or controlling shareholders, mitigating conflict risks.
- A copy of the SPA is available for inspection for three months at the company’s registered office.
Strategic Rationale
The acquisition aligns with HS Optimus’s strategy to secure stable and recurring income streams. Medicorp’s consistent profitability and established relationships with major customers in Brunei’s healthcare and oil & gas sectors provide earnings stability and resilience. The Board believes the transaction is in the best interests of the company and its shareholders, offering enhanced income stability and potential for steady financial performance.
Potential Share Price Movers
- The scale of the acquisition and guaranteed dividends are likely to be viewed favourably by investors seeking growth and stability.
- Share dilution from new share issuance at a discount may be a concern for existing shareholders.
- Successful completion and integration could materially increase HS Optimus’s earnings, driving share price appreciation.
- Any delays or failures in meeting conditions precedent could negatively impact investor sentiment.
Cautionary Note
The SPA is subject to multiple conditions precedent, including regulatory approvals and satisfactory due diligence. Completion is not assured. Investors are advised to monitor further company announcements and consult their financial advisers before making investment decisions.
Disclaimer
This article is for information purposes only and does not constitute investment advice. All information is based on publicly available sources and company announcements. Investors should exercise caution and consult their own advisers before acting on any information herein.
HS Optimus控股有限公司宣布战略收购Medicorp Sdn Bhd
交易要点
- 收购协议：HS Optimus控股有限公司已签署协议，收购Medicorp Sdn Bhd 7,500股普通股，占总股本的30%。
- 卖方认沽权：卖方李瑞仁获授认沽权，可在三年内要求HS Optimus或其子公司再收购4,750股（占19%股本）。
- Medicorp概况：Medicorp是一家文莱医疗设备和耗材供应商，2025年经审计净有形资产为322万文莱元，净利润为147万文莱元。
- 购买对价：总对价为420万新元，分为最多100万新元的新股和剩余现金支付。
- 估值：认沽权行使价为每股560新元，全部认沽股总价266万新元，基于Medicorp估值1,400万新元。
- 分红保障：HS Optimus获保证三年每年不少于30万新元分红，若年化收益超9%还可获3万新元绩效奖金。
- 财务影响：交易预计将提升集团净利润和每股收益（EPS），但因新股发行每股净有形资产略降。
- 预计完成：若条件满足，交易预计于2026年7月20日前完成。
投资者须知重点
- HS Optimus将以每股0.0054新元发行最多185,185,185新股，较市价折让10%。
- 新股发行占现有股本6.9%，收购后占总股本6.4%。
- 现金部分由集团内部资金支付。
- 交易需满足多项前提，包括尽调、独立估值、股东协议、监管批准、业务无重大不利变化等。
- Medicorp可宣布250万新元预先分红，转为无担保股东贷款，偿还受严格条件约束以保障营运资金。
对股价可能有影响的敏感信息
- SPA及认沽权条款有望显著提升HS Optimus盈利，三年分红保障和绩效奖金将提供稳定收入。
- 大量新股折价发行对现有股东可能有稀释影响，影响每股净资产和股价。
- 收购不会导致控股权变更，但将加强HS Optimus在医疗供应领域地位，获得Medicorp稳定客户基础。
- 新股发行及利润贡献符合SGX Catalist规则1006，构成“须披露交易”，投资者值得关注。
- 若前提条件未能全部满足，交易或无法完成，投资者应关注后续公告。
财务影响（模拟）
| 交易前 | 收购后 | 全部交易后 | |
|---|---|---|---|
| 已发行股本（新元） | 103,170,633 | 104,170,633 | 105,170,633 |
| 股数 | 5,380,556,316 | 5,565,741,501 | 5,750,926,686 |
| 净有形资产（千新元） | 49,066 | 50,000 | 51,000 |
| 每股净有形资产（分） | 0.91 | 0.90 | 0.89 |
| 净利润（千新元） | 2,748 | 3,124 | 3,402 |
| 每股收益（分） | 0.05 | 0.06 | 0.06 |
战略意义
收购与HS Optimus战略一致，旨在获取稳定、可持续收入来源。Medicorp持续盈利并拥有文莱医疗和油气行业主要客户，为公司提供业绩稳定性和弹性。董事会认为交易符合公司及股东利益，将提升收入稳定性和财务表现。
股价可能推动因素
- 收购规模及分红保障有望获投资者看好，增强增长和稳定预期。
- 新股折价发行对现有股东有稀释风险。
- 若交易顺利完成并整合，HS Optimus盈利有望大增，推动股价上涨。
- 若条件未能满足，交易延迟或失败可能影响市场情绪。
风险提示
SPA受多项前提约束，包括监管批准和尽调，交易能否完成尚不确定。投资者应关注公司后续公告，并在投资前咨询专业顾问。
免责声明
本文仅供参考，不构成投资建议。所有信息基于公开资料和公司公告。投资者应谨慎操作，并咨询专业顾问后再做决策。
